What is the appropriate antibiotic regimen for a patient with community‑acquired pneumonia who is allergic to azithromycin, doxycycline, and penicillin?

Respiratory Fluoroquinolone Monotherapy

For a patient with community-acquired pneumonia who is allergic to azithromycin, doxycycline, and penicillin, a respiratory fluoroquinolone (levofloxacin, moxifloxacin, or gemifloxacin) is the recommended antibiotic regimen.

Rationale for Recommendation

Given your triple allergy profile, the standard guideline-recommended regimens are eliminated:

• Penicillin allergy excludes all beta-lactams (amoxicillin, cephalosporins, carbapenems)
• Azithromycin allergy excludes macrolides as a class
• Doxycycline allergy removes the tetracycline option

This leaves respiratory fluoroquinolones as the primary evidence-based choice. The 2019 IDSA/ATS guidelines explicitly recommend respiratory fluoroquinolone monotherapy as a strong recommendation with moderate quality evidence for outpatient CAP 1. The 2007 IDSA/ATS guidelines similarly support fluoroquinolone monotherapy for both medical ward and ICU patients 2.

Specific Antibiotic Options

Outpatient or non-severe hospitalized CAP:

• Levofloxacin 750 mg once daily
• Moxifloxacin 400 mg once daily
• Gemifloxacin 320 mg once daily

Severe CAP requiring ICU admission:

• For penicillin-allergic patients with severe pneumonia, guidelines recommend a respiratory fluoroquinolone plus aztreonam 2
• However, given your azithromycin allergy (which may extend to macrolide class), the fluoroquinolone becomes even more critical
• If Pseudomonas is a concern: aztreonam plus levofloxacin 750 mg 2

Alternative Considerations for Beta-Lactam Allergy

Important caveat: True penicillin allergy occurs in only 10% of patients who report it. If your allergy history can be clarified:

• Non-severe reactions (rash without anaphylaxis): Consider cephalosporins, as cross-reactivity is <3% with third-generation agents 3
• Severe IgE-mediated reactions (anaphylaxis, angioedema): Aztreonam has no cross-reactivity with penicillins and can be used 2

For hospitalized patients with confirmed severe beta-lactam allergy, the 2003 IDSA guidelines note that aztreonam plus a respiratory fluoroquinolone is appropriate 3.

Duration and Monitoring

• Minimum 5 days of therapy 2
• Must be afebrile for 48-72 hours before discontinuation
• Should have no more than 1 CAP-associated sign of clinical instability

Critical Safety Warnings

Fluoroquinolone-associated risks that require consideration:

• QT prolongation and cardiac arrhythmias
• Tendon rupture (especially >60 years, corticosteroid use)
• Aortic aneurysm risk (avoid if known aneurysm or vascular disease)
• CNS effects (seizures, confusion)
• Clostridioides difficile infection risk

Despite these concerns, the 2019 guidelines concluded that fluoroquinolones remain justified for CAP given their excellent pneumococcal coverage, low resistance rates, and proven efficacy 1.

Clinical Pearls

Severity assessment determines setting:

• Use pneumonia severity index (PSI) or CURB-65 to guide admission decisions 3
• ICU admission criteria include: respiratory rate >30, PaO2/FiO2 <250, multilobar infiltrates, confusion, uremia, hypotension 2

If no clinical response within 48-72 hours:

• Consider resistant organisms, incorrect diagnosis, or complications (empyema, abscess)
• Obtain blood cultures and sputum cultures before escalating therapy
• Consider bronchoscopy if immunocompromised or non-responding 4

The evidence strongly supports respiratory fluoroquinolones as monotherapy for your specific allergy profile, with excellent coverage of Streptococcus pneumoniae, atypical organisms (Mycoplasma, Chlamydophila, Legionella), and most gram-negative pathogens causing CAP.